Update on Switching Stable 1st and 2nd Line ART Patients to DTG Containing Regimen (TLD Update)
To strengthen the capacity of the health sector to deliver high-quality, comprehensive health services, South Africa adopted the World Health Organization (WHO) recommendations to include Dolutergravir (DTG), as the preferred anti-retroviral drug for first and second line regimens. The 2019 HIV clinical guidelines have been revised to include a new formulation of the fixed dose combination (FDC) of Tenofovir (TDF) 300 mg + Lamivudine (3TC) 300 mg + Dolutegravir (DTG) 50 mg (TLD) for all eligible adults, adolescents and children over 10 years of age and weighing 20kg or more. The principal goal of ART is to attain and maintain viral suppression, which will decrease morbidity and mortality from HIV, as well as improve the quality of life for clients living with HIV. These updates will empower clinicians with the knowledge to provide quality, comprehensive services to the public.
Device (cellphone, tablet, laptop, and/or desktop.
Accessing the course materials and recorded lectures online is free as the Knowledge Hub has been zero rated. An initial internet connection is required to connect to the KH.
The updates includes seven units as follows:
- Dolutegravir
- First-line ART regimens
- Dual treatment of HIV and TB
- Monitoring on ART, switching regimens, and managing an elevated viral load (VL)
- Second line ART
- TB preventative therapy (TPT)
- Switching regimens for second-line clients
Updates objectives:
- Share the latest information on the management of clients on TLD.
- Guide clinicians on the switching of stable second-line clients to the DTG-containing regimen.
- Share the latest information on viral-load monitoring and management.
- Highlight critical areas for the provision of integrated ART, TB and family planning services.
until
31 December 2023 - 12:00 pm